Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

stors. With our clinical programs on track to generate additional data, and contract revenues from Avid and our DTRA program continuing to increase, we anticipate that FY 2010 could be a very positive year for Peregrine."

The company's Annual Report on Form 10-K will be filed later today and will be available at the SEC's website at www.sec.org, or through the investor portion of Peregrine's website at www.peregrineinc.com.

Operating Highlights Since the Start of Fiscal Year 2009

Bavituximab Anti-Cancer Program

Peregrine reported progress in all four ongoing trials in its bavituximab cancer program, including its three Phase II trials:

  • Completed enrollment of the planned 46 patients in a Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. As reported in an oral presentation at the 2009 ASCO Annual Meeting, 10 of 14, or 71% of evaluable patients in the initial cohort demonstrated an objective tumor response according to RECIST criteria. These data exceeded the pre-specified endpoint needed to expand the trial and compare favorably with historical data with chemotherapy alone. Recent analysis shows the median progression free survival of patients enrolled in the first part of the study was 7.4 months, a promising early result. Patient dosing and follow-up in this trial are continuing.
  • Reported that in a Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients, nine of 14, or 64% of evaluable patients in the initial cohort achieved an objective tumor response according to RECIST criteria. These data exceeded the pre-specified endpoint needed to expand the trial. Patient enrollment and dosing are underway in the
    '/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Access to Quality, Cost-Effective Care , ... Washington, D.C. ... debated the best ways to rein in runaway costs while providing ... important part of the ongoing discussion includes how to ensure patients ... doctors of medicine (MDs) or osteopathy (DOs). In both the ...
(Date:12/16/2009)... link has been found, , , WEDNESDAY, Dec. 16 (HealthDay ... linked to food poisoning and the stomach pain and ... of some urinary tract infections. , Researchers have found ... stores and restaurants and in women with the infections. ... transmitted directly to the women through the food they ...
(Date:12/16/2009)... Therapy or NSRTSM is found very effective in the alleviation ... asthma, migraines, chronic fatigue and a wide array of skin ... using this holistic therapy including over 50 branded BioVeda Health ... ... MN (Vocus) December 14, 2009 -- BioVeda Health and Wellness ...
(Date:12/16/2009)... Age should not be determining factor for use, expert ... people with heart failure are much less likely to ... a new study. , The study included 4,685 people, ... device and had a left ventricular fraction (a measure ... less. , During a three-year period, those who were ...
(Date:12/16/2009)... shows, , , WEDNESDAY, Dec. 16 (HealthDay News) -- Average ... 78 years, a record high, federal health officials said ... to live to 80.4 years on average and men ... U.S. Centers for Disease Control and Prevention. , ... than their parents, life expectancy in the United States ...
Breaking Medicine News(10 mins):Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5Health News:Implanted Defibrillator Might Extend Life 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3
... Digest: , , Summary of study being ... Journal of Clinical Oncology ,showing no survival difference ... ovaries were left intact during cancer surgery compared ... for attribution from Beth Karlan, MD, American Society ...
... ease psychological distress and depressive symptoms often suffered ... at Universit Laval,s Faculty of Medicine. Their study, ... American Journal of Clinical Nutrition , presents the ... treating common menopause-related mental health problems. , Dr. ...
... by means of metal electrodes, in the hope of both ... conditions such as blindness or epilepsy. In the future, the ... nerve cells grown for that purpose. In research that was ... Prof. Elisha Moses of the Physics of Complex Systems Department ...
... 28 Each Sunday throughout February, Sharing Miracles ... the compelling and inspirational stories of real patients, will ... Elyse Keaton on the hit sitcom Family Ties ... 250 television stations across the United States. Though perhaps ...
... SmoothShapes(R) Premiers at the Leading Cellulite Treatment Clinic in ... Inc., a premier aesthetics company focused on body shaping, ... owners of Anushka Spa & Cosmedical Centre in West ... will be the first treatment center in the Palm ...
... data shows little difference from placebo , , WEDNESDAY, Jan. ... acupuncture offers only limited relief that may not be ... data from 13 acupuncture pain studies that included more ... placebo acupuncture and no acupuncture for a wide range ...
Other Medicine News:Health News:Study shows younger women with endometrial cancer can safely keep ovaries, avoid early menopause 2Health News:Omega-3s ease depressive symptoms related to menopause 2Health News:Weizmann Institute scientists create working artificial nerve networks 2Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Nominated Actress Meredith Baxter 2Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Nominated Actress Meredith Baxter 3Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Nominated Actress Meredith Baxter 4Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Nominated Actress Meredith Baxter 5Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Nominated Actress Meredith Baxter 6Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Nominated Actress Meredith Baxter 7Health News:Anushka * Cellulite Clinic * Cosmedical Centre Introduces Next Generation Cellulite Treatment 2Health News:Anushka * Cellulite Clinic * Cosmedical Centre Introduces Next Generation Cellulite Treatment 3Health News:Pain-Relieving Powers of Acupuncture Unclear 2
(Date:12/16/2009)... Cohera Medical Inc. today announced the treatment of ... lead surgical adhesive product, TissuGlu®. Initiation of the ... progression of the lead product toward clinical practice. ... open-label, randomized study to investigate the safety of ... associated complications in abdominoplasty, or "tummy tuck," surgeries. ...
(Date:12/16/2009)... Dec. 16 RealMed has been ... in the 2009 Top 20 Best ... report. RealMed is a dynamic revenue ... transactions processing between healthcare providers and ... research firm specializing in vendor performance measurement ...
(Date:12/16/2009)... CareCentrix, Inc ., the nation,s leading provider ... that it has been awarded Health Utilization Accreditation ... organization that establishes quality standards for the health ... trained, qualified clinical personnel conduct and oversee the ... appeals process is in place, and that medical ...
Breaking Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3CareCentrix Receives URAC Health Utilization Management Accreditation 2High Impact Activity May Be Good for Old Bones 61359 1High Impact Activity May Be Good for Old Bones 61359 2blue sky scrubs adds Caribbean Blue Scrubs 61357 1blue sky scrubs adds Caribbean Blue Scrubs 61357 2U S Census Bureau Daily Feature for Nov 14 61355 1
... Improved Efficacy with Higher Doses ... - ... - Dose Escalation Ongoing -, SAN FRANCISCO and ... an ongoing Phase 1-2,clinical trial of the Company,s novel androgen receptor antagonist,MDV3100, showed encouraging ...
... "A two-year,survival rate of more than ... suggests a breakthrough in this devastating disease ... and Coordinating,Investigator of the Phase IIb active-controlled ... refractory high-grade glioma, while presenting the,data at ...
Other Medicine Technology:Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 4Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 2Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 3Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 4
... provides fast, accurate, and reliable tests of a ... duplicates conditions for viewing far point test charts ... near point test charts at 30cm (12"). The ... test charts that can be interchanged as required. ...
A professionally designed instrument for obtaining accurate measurements of the corneal curvature. The convenient configuration also facilitates measuring contact lens curvatures....
... the benefits of IMAGEnet Lite, a standard ... PC with the Topcon TRC-NW6 or TRC-NW6S ... fundus screening package. The system incorporates the ... Topcons Non-Mydriatic retinal camera allowing a technician ...
... combines the best 32-bit software package (IMAGEnet ... offerings to bring you a fast reliable ... efficient "mid-resolution" package takes advantage of the ... the latest graphics capture technology and a ...
Medicine Products: